martes, 31 de octubre de 2017

Journal for ImmunoTherapy of Cancer | Home page

Journal for ImmunoTherapy of Cancer | Home page

Journal for ImmunoTherapy of Cancer
Editor-in-Chief: Professor Pedro Romero

This year Journal for ImmunoTherapy of Cancer will once again be exhibiting at the Society for Immunotherapy of Cancer (SITC) Annual Meeting. Find us at the SITC booth where you can learn more about how the journal’s publishing policies empower authors and their research—a tangible effort to incentivize open collaboration. Click here for featured articles related to the conference.

Journal Scope
Journal for ImmunoTherapy of Cancer (JITC) is an open access, peer reviewed journal that encompasses all aspects of tumor immunology and cancer immunotherapy, from basic research through to clinical applications.

JITC welcomes submissions to the following sections:
Basic Tumor Immunology - edited by Cornelis J. Melief
Case Reports - edited by Alfred Zippelius
Clinical Trials Monitor - edited by Leisha A. Emens
Clinical/Translational Cancer Immunotherapy - edited by
James L. Gulley
Commentary/Editorials - edited by Christian Capitini
Guidelines and Consensus Statements - edited by Robert L. Ferris
Immunotherapy Biomarkers - edited by Lisa H. Butterfield
Reviews - edited by Thomas F. Gajewski and Per Thor Straten

Reasons to Publish with Us
The official journal of the Society for Immunotherapy of Cancer (SITC)
Free article processing charges for SITC members
Distributed to over 15,000 individuals in the cancer treatment space and downloaded more than 800,000 times in 2015

Register to receive the latest articles, straight to your inbox.

Best wishes,

Journal for ImmunoTherapy of Cancer


Follow BioMed Central:

For further information or enquiries please contact Customer Services
BioMed Central Ltd
236 Gray's Inn Road, London, WC1X 8HB,
United Kingdom.


No hay comentarios:

Publicar un comentario